SCHEMBL1474491

SCHEMBL1474491

COc1cccnc1N1CCN(CCNC(=O)c2cc(-c3ccco3)on2)CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.56
HSD17B10 Q99714 1/20 0.56
ALDH1A1 P00352 5/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
LMNA P02545 2/20 0.55
MAPT P10636 1/20 0.55
HTT P42858 1/20 0.55
HTR1A P08908 1/20 0.54
ADRA1A P35348 1/20 0.54
NPC1 O15118 3/20 0.52
RAB9A P51151 2/20 0.52
TP53 P04637 1/20 0.52
GAA P10253 1/20 0.52
HPGD P15428 1/20 0.52
DRD3 P35462 2/20 0.52
DRD2 P14416 1/20 0.52
MEN1 O00255 1/20 0.48
KLK7 P49862 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1474416 0.89 ALDH1A1 (0.55) KDM4EHSD17B10ALDH1A1SMN1; SMN2LMNA
SCHEMBL15190242 0.88 ALDH1A1 (0.45) KDM4EHSD17B10ALDH1A1SMN1; SMN2LMNA
SCHEMBL1474730 0.87 ALDH1A1 (0.68) KDM4EHSD17B10ALDH1A1SMN1; SMN2LMNA
SCHEMBL1474501 0.85 RAB9A (0.50) KDM4EALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL1475249 0.85 RAB9A (0.58) KDM4EHSD17B10ALDH1A1SMN1; SMN2LMNA
SCHEMBL1477057 0.84 ALDH1A1 (0.64) KDM4EHSD17B10ALDH1A1SMN1; SMN2LMNA
SCHEMBL1474506 0.83 ALDH1A1 (0.58) KDM4EHSD17B10ALDH1A1SMN1; SMN2LMNA
SCHEMBL1474944 0.83 ALDH1A1 (0.56) KDM4EHSD17B10ALDH1A1SMN1; SMN2LMNA
SCHEMBL1475255 0.82 ALDH1A1 (0.62) KDM4EHSD17B10ALDH1A1SMN1; SMN2LMNA
SCHEMBL1474658 0.82 NPC1 (0.55) ALDH1A1SMN1; SMN2LMNAHTR1ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 KDM4E 4278/4885HSD17B10 2297/4885ALDH1A1 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.